Evaluating Renal Benefits of Rivaroxaban Versus Vitamin K Antagonists in Atrial Fibrillation: A Systematic Review and Meta-analysis of Real-world Evidence

被引:0
|
作者
Dinh, Phong Phan [1 ,2 ]
Ho, Tri Huynh Quang [3 ]
Pham, Hung Manh [1 ,2 ,6 ]
Nguyen, Hai Hoang [4 ]
Ton, Minh That [5 ]
Tran, Giang Song [1 ]
Vu, Nga Quynh [6 ]
Pham, Hung Nhu
Cao, Son Luong [7 ]
Hoang, Sy Van [8 ,9 ]
机构
[1] Bach Mai Hosp, Vietnam Natl Heart Inst, Hanoi, Vietnam
[2] Hanoi Med Univ, Hanoi, Vietnam
[3] Heart Inst, Surg Intens Care Unit, Ho Chi Minh City, Vietnam
[4] Nhan Dan Gia Dinh Hosp, Ho Chi Minh City, Vietnam
[5] Tam Duc Heart Hosp, Ho Chi Minh City, Vietnam
[6] Hanoi Heart Hosp, Hanoi, Vietnam
[7] Univ Med Ctr Ho Chi Minh City, Dept Cardiol, Ho Chi Minh City, Vietnam
[8] Cho Ray Hosp, Cardiovasc Dept, Ho Chi Minh City, Vietnam
[9] Univ Med & Pharm Ho Chi Minh City, Ho Chi Minh City, Vietnam
关键词
Rivaroxaban; AF; acute kidney injury; renal failure; anticoagulant -related nephropathy; CHRONIC KIDNEY-DISEASE; CLINICAL-TRIALS; OUTCOMES; RISK; ANTICOAGULANTS; WARFARIN; DECLINE; INJURY;
D O I
10.15420/ecr.2024.07
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: AF is a global health concern, with systemic complications including renal dysfunction. This systematic review and meta-analysis compares the effects of rivaroxaban, a Factor Xa inhibitor, and vitamin K antagonists (VKAs) on renal outcomes in AF patients. Methods: The study protocol is registered in PROSPERO (ID: CRD42023462756). We systematically searched the PubMed, Embase and Cochrane Library databases from 1 January 2017 to 30 June 2023 for real-world studies comparing the effects of rivaroxaban and VKAs on renal outcomes in AF patients, including acute kidney injury, a >= 30% decrease in estimated glomerular filtration rate, doubling of serum creatinine and worsening renal function. Subgroup analyses targeted diabetes, pre-existing kidney disease, the elderly (age >= 65 years) and Asian populations. The risk of bias was assessed used the Robins-I tool. HRs and 95% CIs were synthesised through a random-effects model. Two sensitivity analyses were performed, using a fixed-effects model and excluding conference abstracts. Results: We identified 1,666 records. After screening, 14 studies comparing rivaroxaban and VKAs were included. Rivaroxaban exhibited superiority over VKAs in preventing: acute kidney injury (HR 0.68; 95% CI [0.61-0.77]; p<0.00001); a >= 30% decrease in estimated glomerular filtration rate (HR 0.71; 95% CI [0.60-0.84]; p<0.0001); doubling of serum creatinine (HR 0.50; 95% CI [0.36-0.70]; p<0.0001); and worsening renal function (HR 0.56; 95% CI [0.45-0.69]; p<0.00001). Subgroup and sensitivity analyses consistently confirmed rivaroxaban's favourable effects on renal outcomes in diabetes, pre-existing kidney disease, the elderly and Asian populations. Conclusion: Our findings support the preference of rivaroxaban over VKAs for renal outcomes in AF. The findings endorse rivaroxaban as the preferred anticoagulant to mitigate renal complications, offering clinicians valuable insights for tailored strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation - a network meta-analysis of real-world data
    Hirschl, Mirko
    Kundi, Michael
    VASA-EUROPEAN JOURNAL OF VASCULAR MEDICINE, 2019, 48 (02) : 134 - 147
  • [42] Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis
    Weeda, Erin R.
    White, C. Michael
    Peacock, W. Frank
    Coleman, Craig I.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (06) : 1117 - 1120
  • [43] Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis
    Deitelzweig, Steven
    Bergrath, Evelien
    di Fusco, Manuela
    Kang, Amiee
    Savone, Mirko
    Cappelleri, Joseph C.
    Russ, Cristina
    Betts, Marissa
    Cichewicz, Allie
    Schaible, Kassandra
    Tarpey, Jialu
    Fahrbach, Kyle
    FUTURE CARDIOLOGY, 2022, 18 (05) : 393 - 405
  • [44] Real-world experience in managing atrial fibrillation in patients with renal impairment; Rivaroxaban versus warfarin
    Albabtain, Monirah Abdulrahman
    Alanazi, Zaid Dakheel
    Al-Mutairi, Nawaf Hamoud
    Alyafi, Ola
    Albanyan, Raneem
    Arafat, Amr A.
    HEART VIEWS, 2023, 24 (03): : 136 - 140
  • [45] DOES RIVAROXABAN REDUCE THE DEVELOPMENT OF RENAL FAILURE COMPARED TO VITAMIN K ANTAGONIST USE IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS? A SYSTEMATIC REVIEW AND META-ANALYSIS
    Costa, O.
    Baker, W.
    Coleman, C.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 652 - 652
  • [46] Novel Oral Anticoagulants versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Concomitant Valvular Heart Disease: A Systematic Review and Meta-Analysis
    Memon, Muhammad
    Siddiqui, Asad Ali
    Tarique, Khadijah Ahmad
    Amin, Emaan
    Khan, Mohammad
    Doukky, Rami
    Krasuski, Richard
    CIRCULATION, 2021, 144
  • [47] DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN/VITAMIN K ANTAGONISTS FOR STROKE PREVENTION IN FRAIL PATIENTS WITH ATRIAL FIBRILLATION: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Jain, Akhil
    Shenwai, Priya
    Lakshmanan, Ankita
    Mohammad, Aamer
    Merugu, Neha Bhavyasri
    Gaddam, Neelima
    Guzman, Frailyn Nunez
    Itare, Vikram
    Raina, Jilmil
    Desai, Rupak
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 46 - 46
  • [48] EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS VERSUS VITAMIN K ANTAGONISTS IN PATIENTS WITH ATRIAL FIBRILLATION AND BIOPROSTHETIC VALVES: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Patel, Neha
    Elzanaty, Ahmed
    Patel, Mitra
    Elsheikh, Eman
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 1727 - 1727
  • [49] Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis
    Troisi, Federica
    Guida, Pietro
    Vitulano, Nicola
    Quadrini, Federico
    Di Monaco, Antonio
    Grimaldi, Massimo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 379 : 40 - 47
  • [50] Response by Bai et al to Letter Regarding Article, "Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis"
    Bai, Ying
    Shantsila, Alena
    Lip, Gregory Y. H.
    STROKE, 2017, 48 (06) : E149 - E149